

# Comparison of Genome Aberrations Between Early-Onset and Late-Onset Breast Cancer

Ming-Ta Hsu et al.\*

*Institute of Biochemistry and Molecular Biology, VGH-YM Genome Center,  
National Yang-Ming University, Taipei,  
Taiwan*

## 1. Introduction

Breast cancer is the most common cancer and the second leading cause of cancer deaths in women worldwide. Breast cancer statistics in the US shows a bimodal distribution consisting of early-onset and late-onset patients. Although the incidence of early-onset breast cancer in western population is low, the survival rate is significantly poorer before 40 years old (Yankaskas, 2005). Bonnier and his colleagues showed that the breast cancer patients under 35 years old also have poorer prognostic and possess the following characteristics: (1) a higher frequency of undifferentiated tumors, (2) histoprognostic grade-III cancer, (3) microscopic lymph-node involvement and (4) negative hormonal receptor status (Bonnier et al., 1995).

Although incidence rate of breast cancer has been decreasing in the US, this happens only in the late-onset age group (Benz, 2008). Asian women have significant lower incidence rate of breast cancer (about 25/100000 in Eastern Asia) than the western countries (about 90/100000 in Western Europe) but the rate of incidence is increasing steadily with the improvement of economics in the area. In Taiwan, the incidence of breast cancer has dramatically increased from about 13/100000 in 1980 to 49/100000 in 2005 (Chang et al., 2008). The increase in breast cancer in Asia is different from that of western countries in that the incidence of premenopausal breast cancer is proportionally higher in the Asian women. Similar trend of early-onset breast cancer is found in Africa (Kruger et al., 2007).

According to clinical statistics, breast cancer patients in Taiwan are mainly identified 10 years younger than their counterparts in the western countries. Compared with the late-onset group, the early-onset breast cancer (age < or = 40) has a more aggressive clinical behavior, and its five-year survival rate for each stage is much poorer. One unique feature in

---

\*Ching Cheng<sup>1</sup>, Chian-Feng, Chen<sup>2</sup>, Yiin-Jeng Jong<sup>4</sup>, Chien-Yi Tung<sup>3</sup>, Yann-Jang Chen<sup>4</sup>, Sheng Wang-Wuu<sup>4</sup>, Ling-Hui Li<sup>4</sup>, Shih-Feng Tsai<sup>4</sup>, Mei-Hua Tsou<sup>3</sup>, Skye H. Cheng<sup>5</sup>, Chii-Ming Chen<sup>5</sup>, Andrew T. Huang<sup>5</sup>, Chi-Hung Lin<sup>3</sup> and Ming-Ta Hsu<sup>1,2</sup>

<sup>1</sup>*Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan*

<sup>2</sup>*VGH-YM Genome Center, National Yang-Ming University, Taipei, Taiwan*

<sup>3</sup>*Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan*

<sup>4</sup>*Institute of Genome Sciences, National Yang-Ming University, Taipei, Taiwan*

<sup>5</sup>*Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan*

Taiwan is the large proportion of early-onset breast cancer (Cheng et al., 2000). Compared with the late-onset group, the early-onset breast cancer (age  $\leq$  40) has a more aggressive clinical behavior, and its five-year survival rate for each stage is much poorer. The early-onset breast cancer has poorer prognostic features. Standard pathologic factors are not good predictors of their outcome. Several studies have correlated the breast cancer subtypes with early-onset breast cancer recently (Anders et al., 2008; Lin et al., 2009; Sorlie et al., 2003; Sotiriou et al., 2003). The classification of subtypes has been shown to provide prognostic information and etiologic mechanisms of breast cancer. In Taiwan, the young women breast cancer tends to be more luminal A type with higher ER and PR expression and less basal-like subtype than that of the older women (Cheng et al., 2000; Lin et al., 2009), but with higher risk of second primary malignancy and worse prognosis (Lee et al., 2008; Mellekjaer et al., 2006; Yu et al., 2006). This feature is quite distinct from that of western developed countries with high prevalence of more aggressive basal-like breast cancer in young women. In western populations, younger women are more likely to have biologically aggressive breast cancer as shown by higher proportions of ER-negative and histologic grade III tumors compared with older patients (Anderson et al., 2002; Anderson et al., 2001; Colleoni et al., 2002). Anders and the colleagues also reported that more aggressive subtypes, such as basal-like subtype, would be over-represented among breast cancer arising in early-onset patients, whereas older women would more commonly be diagnosed with luminal tumors in the USA (Anders et al., 2011). The increasing incidence of breast cancer in the young women population is worrisome since they constitute a major labor force and are also potential mothers who need to take care of young children. It is therefore important to understand the epidemiological as well as genetic origin of the rising incidence of early-onset breast cancer with possible implications in prevention as well as diagnostic/prognostic applications.

Etiological factors of breast cancer are complex. Reproductive history, diet, alcohol, and body size among others have been implicated (Jevtic et al., 2010; McTiernan et al., 2010; Phipps et al., 2011). Among these factors reproductive history has been found to be strongly correlated with breast cancer is reproductive history. Since the early observation of high incidence of breast cancer among nuns in eighteenth century nulliparity and older age at first birth have been strongly associated with incidence of breast cancer (Butt et al., 2009; Muti, 2005; Trichopoulos et al., 2008; Wu et al., 2011; Yaghjian and Colditz, 2011). Both nulliparity and older age pregnancy and child birth are characteristics of developed countries and countries with rapid economic growth as in Taiwan. This may partly explain the rapid rise of this disease here.

The association of reproductive history and breast cancer might be understood from hormone target theory (Adami et al., 1995; Adami et al., 1998; Cerliani et al., 2011; Trepp et al., 2010). Mammary gland formation consists of three stages: *organogenesis*, which grows from terminal end bud (TEB) to non-pregnant primary ductal system with cuboidal epithelial cells and is stimulated by prolactin; mature gland formation, with highly branched ducts and lobular buds; pregnancy gland formation, through the stimulation of several hormones with differentiation of lobular buds into fully differentiated type III lobules with milk secreting columnal cells. These complicated differentiation processes involve temporal controls from hormones, cytokines, specific transcription factors, growth factors as well as contribution from stromal elements including myoepithelial cells, base membrane and a collection of integrins (Ahmad and Kumar, 2011; Chen and Capocchi, 1999; Chodosh et al., 1999; Flucke et al., 2010; Howell and Evans, 2011; Li et al., 2010; Okoh et al.,

2011; Tamimi et al., 2011). As a major organ involved in pregnancy the major player in mammary gland development is hormone. Induction of cell differentiation by hormone during pregnancy provides protection against tumorigenesis because the epithelial cells become fully differentiated and are not susceptible to carcinogens. This explains the role of parity in breast cancer. The better protection for earlier pregnancy can be explained by the smaller hormone targets and the less chance to accumulate deranged cells.

According to the hormone target theory, stimulation of cell growth of undifferentiated epithelial cells in immature mammary gland may provide a mechanism for early-onset breast cancer. The predominance of immature epithelial cells in embryo provides the target for the initiation of tumorigenesis when intrauterine hormone concentration is high. Indeed, animal studies showed that undifferentiated TEB is the most susceptible to carcinogen for the formation of tumor (Bai and Rohrschneider, 2010; Roussos et al., 2010; Russo and Russo, 1994). Recent evidence even points to the immature gland in utero as the target for the initiation of breast cancer (Brisken and O'Malley, 2010; Hardy et al., 2010; Hilakivi-Clarke and Clarke, 1998; Sanderson et al., 1998; Torres-Arzayus et al., 2010).

Although there is intensive study of the genetic pathways involved in breast tumorigenesis, the genetic basis of the breast cancer in young women and the differences between early-onset and late-onset tumors remain largely unknown. The different pathological features of the two types of cancer suggest that they have different genetic origin. In order to explore the genetic basis of early-onset and late-onset breast cancer, we analyzed the candidate genes associated with the chromosomal aberrations in these two types of cancer from data in the public domain as well as from our own array-CGH data from the patients in Taiwan through literature search of involvement of genes in the aberration regions. Furthermore, the differential gene expression of these two types of cancer is analyzed by SAGE technique to deduce the genes that may be specifically related to early-onset cancer.

## **2. Comparison of genomic aberrations between early- and late-onset breast cancer**

Breast cancer frequently contains amplification in several regions of chromosomes. Recent advances in high resolution array-CGH analysis and the availability of human genome sequence enabled finding candidate genes involved in breast cancer from these chromosomal aberration regions. We are interested in studying genes associated with early-onset (age <40) breast cancer which has become a major health concern in Taiwan. Early-onset breast cancer has poor prognosis compared with late-onset (age >70) breast cancer and genomics analysis indicated that they have different chromosomal and genetic aberration profiles, suggesting they have different origins. In this article we summarized the current candidate genes involved in breast cancer from genomic data and presented data on genetic differences between the two types of breast cancer. The possible implication in the genetic differences is discussed.

### **2.1 Review of chromosome aberrations in early- and late-onset breast cancer and candidate genes associated with tumorigenesis**

To explore the genes differentially associated with early-onset and late-onset breast cancers, we first collected the aCGH data in the Progenetix database ([www.progenetix.net](http://www.progenetix.net)) (Baudis and Cleary, 2001; Boldt et al., 2010; Fridlyand et al., 2006; Reis-Filho et al., 2005) and reanalyzed the data. All the samples were regrouped based on the age of patients: younger

and elder groups were defined as less than 46 and more than 70 years old respectively. Then the frequency of copy number gains or losses (y axis) were plotted with the probes along with the chromosome order (x axis). As the frequency lower than 10% may reflect the randomly change dues to the genomic instability of tumor, we define gain or loss more than 30% as significant aberrations. Early or late onset-specific aberrations were defined as gain or loss more than 30% and higher than the other group at least 15%. When these data are lined up chromosome-by-chromosome (Fig. 1), regions of chromosome aberrations common to both groups as well as specific to each group can be discerned (Table 1). Genes within each regions identified are then examined through literature search to identify candidate genes involved in breast carcinogenesis (Table 2, and 3). Genes that are either down-related or suppress tumorigenesis are in italic.




Fig. 1. Chromosome aberrations in early- and late-onset breast cancer.

	Gains		Losses	
Early onset	Ch1	41~42Mb	-	-
	Ch1	148~157Mb	-	-
	Ch3	161~172Mb	-	-
	Ch7	150~151Mb	-	-
	Ch9	0~14Mb	-	-
	Ch13	103~112Mb	-	-
Late onset	Ch16	7~25Mb	Ch16	74~81Mb
Common	Ch1	175~247Mb	Ch8	3~32Mb
	Ch8	48~114Mb	Ch11	108~114Mb
	Ch20	50~51Mb	Ch17	0~9Mb

Table 1. Aberrant chromosomal regions in Breast Cancer Patients.

Early-onset	GAINS	Chr1 41~42Mb	MIRN30E
		Chr1 148~157Mb	ECM1, HORMAD1, CTSS, CTSK, ARNT, PRUNE, S100A10, S100A11, FLG, HAX1, PYGO2, CKS1B, ADAM15, MUC1, NES, NTRK1
		Chr3 161~172Mb	PRKCI, SKIL
		Chr7 150~151Mb	ABCF2, RHEB KCNH2
		Chr9 0-14Mb	VLDLR
Late-onset	GAINS	Chr16 7~25Mb	CIITA, SOCS1 MIRN193B, PALB2
	LOSSES	Chr16 74~81Mb	CNTNAP4, ADAMTS18, WWOX, HSD17B2

Table 2. Aberrations in early-and late-onset breast cancer.

Totally, there are 6 early-onset specific gains on the chromosomes 1 (41-42Mb; 148-157Mb), 3 (161-172Mb), 7 (150-151), 9 (0-14Mb) and 13 (103-112Mb), one late-onset specific gain on chromosome 16(7-25Mb), three common gains on chromosomes 1 (175-247Mb), 8 (48-114Mb) and 20 (50-51Mb). There is a late-onset specific loss in chromosome 16 (74-81Mb) and common loss on chromosomes 8 (3-32Mb), 11 (108-114Mb) and 17 (0-9Mb). Genes that have been shown to be involved in breast carcinogenesis in these regions through literature search are listed in Table 2 and 3.

Interestingly, the early onset-specific aberrations contain more IGF-1 and ER signaling associated genes than the late onset. Candidate genes present in the IGF-1, ER and TGF-beta pathways in both groups of breast cancer patients are listed in Table 4.

The association of ER genes with early-onset cancer is expected since these patients are premenopausal. Since IGF-1 pathway plays an important role in breast tumorigenesis, the genes specific for the late and early-onset cancer are depicted in Fig. 2 to illustrate their positions in the pathway.

## 2.2 Clustering of breast cancer related genes in chromosome regions

A striking feature of the analysis of genes associated with gain or loss in breast cancer chromosomes is that the regions often harbor breast cancer related genes in a cluster fashion and demarked by the presence of genes down-regulated or are anti-tumorigenic in breast cancer.

GAINS	<i>Chr1</i> <i>175~247Mb</i>	PTGS2, PLA2G4A, RGS2, KIF14, LAD1, TIMM17A, ELF3, UBE2T, JARID1B, ADIPOR1, ADORA1, PCTK3, IKBKE, MAPKAPK2, CD55, CD46, NEK2, DTL, ATF3, ESRRG, GPATCH2, TGFB2, DUSP10, ENAH, EPHX1, PARP1, WNT9A, WNT3A, ARF1, EXO1, AKT3, SMYD3 <i>RGSL1, RNASEL, RGS16, BTG2, KISS1, RASSF5, IL10, LAMB3, IRF6, PROX1, PTPN14, TLR5, T53BP2, FH, CHM</i>
	<i>Chr8</i> <i>48~144Mb</i>	SNAI2, LYN, SDCBP, ASPH, COPS5, PRDM14, NCOA2, TPD52, FABP5, E2F5, WWP1, CPNE3, MMP16, CCNE2 TSPYL5, MTDH, LAPT4B, YWHAZ, CTHRC1, ANGPT1, EIF3E, EBAG9, TRPS1, RAD21, TNFRSF11B, HAS2, ATAD2, TRMT12, TATDN1, SQLE, MYC, PVT1, DDEF1, WISP1, PTP4A3 <i>CEBPD, PRKDC, RB1CC1, SOX17, CRH, VCP1P1, SGK3, SULF1, DECR1, TP53INP1, STK3, UBR5, DPYS, NOV, MTSS1, NDRG1</i>
LOSSES	<i>Chr8</i> <i>3~32Mb</i>	ANGPT2, CTSB, EGR3, LOXL2, NKX3-1, STC1, CLU, PBK <i>CSMD1, MCPH1, MSRA, GATA4, DLC1, MTUS1, ASAH1, NAT1, PSD3, LZTS1, PDLIM2, RHOBTB2, BNIP3L, EPHX2, DUSP4, PPP2CB, WRN, NRG1</i>
	<i>Chr11</i> <i>108-114Mb</i>	- <i>PPP2R1B</i>
	<i>Chr17</i> <i>0~9Mb</i>	MYBBP1A, PELP1, PLD2, NUP88, <i>MIRN22, SMYD4, HIC1, MNT, ALOX15, CXCL16, PFN1, XAF1, MIRN195, MIRN497, CLDN7, GPS2, SHBG, ATP1B2, TP53</i>

Table 3. Aberrations in both early- and late-onset breast cancer.

	IGF-1 Signaling	Estrogen Receptor Signaling	TGF-Beta Signaling
Early onset specific aberrations	IRS2, JAK2, PRKAG2, PRKCI, SHC1	SHC1, HIST2H3C	
Late onset specific aberrations	SOCS1		
Common aberrations	AKT3, NOV, PIK3C2B, PIK3R5, PTK, YWHAZ, YWHAZ	H3F3A/H3F3B, HIST3H3, MED30, MED31, NCOA2, PELP1, POLR2A, POLR2K, PRKDC, TAF2, TAF5L	TGFb2

Table 4. The relationship of aberrant genes and IGF-1, ER, and TGF- signal pathways.




Fig. 2. IGF-1 signal pathway.

For example, 198-201Mb in 1q32.1 contains eight genes related to breast tumorigenesis, KLF14, LAD1, TIMM17A, ELF3, UBE2T, JARID1B, ADIPOR1 and ADORA1 as well as a gene CARP1 that is over-expressed in cancers (Fig. 3 shows the distribution of genes positively correlated with breast cancer as red line and negatively correlated with breast cancer as green). We also observed the clustering of the genes that inhibits breast tumorigenesis or are down-regulated in breast cancer in chr17 0-9Mb region that is often deleted in breast cancer. These are mir-22, SMYD4, HIC1, MNT, ALOX15, CLCX16, PFN1, XAF1, mir-195, mir-497, CLDN7, GPS2, SHBG, ATP1B2, and TP53. The pro- and anti-tumorigenesis genes are often found clustered together in a region of the chromosome.

### 2.3 Comparison of chromosome aberrations between early-onset and late-onset breast cancers in Taiwan

To investigate the gene aberrations between early-onset and late-onset breast cancer in Taiwan, we have used Vysis GenoSensor™ Array 300 microarray chip, containing 378 target clone DNA (P1, BAC or PAC clones) representing regions that are important in cytogenetics and oncology, to analyze 15 early-onset and 15 late-onset breast cancer samples. The tissue samples of primary breast cancers were obtained by either biopsies or surgical excision from Koo Foundation Sun Yat- Sen Cancer Center (KF-SYSCC), Taipei, Taiwan. Instead of metaphase chromosome in conventional CGH, BAC or PAC DNAs are

used as hybridization template in array-CGH, which can increase resolution up to approximate 100 kb.




Fig. 3. Common genomic aberration in both early- and late-onset breast cancers. Left panel shows the amplified regions and right panel shows the deleted regions in breast cancers. The red and green lines represent the gene position in the genome. Red lines indicate genes positively correlated with breast cancer and green lines indicate negatively correlated with breast cancer.

The genes present in the most frequent gain or loss regions of early-onset and late-onset breast cancer in Taiwan were analyzed by array-CGH. The genes related to breast cancer in these regions are shown in Table 5. There are two regions differentially gained or loss in late-onset and three regions differentially gained or loss in early-onset. As in the results above, the regions are marked by the presence of both pro- and anti-tumor genes (*in italic*) except 17q23 which is amplified in a subset of early-onset cancer but in none of the late-onset cancer. We analyzed the genes of this region flanking our array-CGH BAC probes. It contains seven genes involved in breast tumorigenesis and represents a region of interest for early diagnosis of breast cancer in young women.

#### 2.4 SAGE analysis of gene expression in early- and late-onset breast cancer in Taiwan

We analyzed 10325 SAGE Taq sequences, and classified SAGE data into two groups (evaluated significance by monte-carol algorithm). There are 460 genes related to the early-onset group, and 214 genes involved in late-onset breast cancer.

SAGE analysis found 12 breast cancer related genes highly prevalent in early-onset than late-onset. Among these genes, cytokeratin 5 and 17 are basal cell markers and are often found in



basal-like and triple-negative breast cancer subtypes. Luminal specific cytokeratin KRT8 and KRT19 was also found to be enriched in early-onset cancer. This result suggests that there are two different subtypes, basal-like and luminal groups, of breast cancer in the early-onset samples we analyzed. Both tumor promoting and inhibiting genes are found expressed in the SAGE data. For example, KLK6 inhibits EMT and its expression is negatively correlated with breast cancer metastasis (Pampalakis et al., 2009) and FLNA (filamin A) is known to suppress breast cancer migration and invasion (Xu et al., 2010). The expression of the tumor suppressive CDH1, CDH13, CTNNB1, SFN, NDRG1 and PFN1 in early-onset tumor also suggests the less invasive nature. IGFBP4 is positively correlated with ER and PR but negatively correlated with Her2 and has better disease outcome (Mita et al., 2007). On the other hand, S100P and LCN2 promote breast cancer progression. Whether the expression of tumor suppressive genes reflects the more benign nature of the early-onset breast cancer or due to mutations in these genes remain to be studied. Genes associated with tumor progression, metastasis and poor prognosis such as CXCR4, ERBB2, TOB1, EZH2, HIF1A, S100A7, are found significantly more expressed in the late-onset breast cancer. The overall expression pattern suggests that the late-onset tumors are more advanced in tumorigenesis than that of the early-onset tumors which constitute mostly benign luminal A subtype in Taiwan.

Cyto Location	Gene related to breast cancer	Early-onset (n=15)	Late-onset (n=15)	P- value
<b>Gains</b>				
16p13.3	MSLN, CACNA1H, PDPK1, SRMM2, TRAP1 <i>STUB1, TSC2, PKD1, ABCA3, DNAJA3</i>	6.67%	60.00%	0.0026
8q11	PRKDC, SNAI2 <i>CEBPD, MCM4, ST18, RB1CC1</i>	6.67%	46.67%	0.0176
16q23.2	-	53.33%	13.33%	0.0251
20q12-q13.1	PLCG1, ADA, WISP2, CD40, NCOA3, SULF2, PREX1 <i>PTPRT, MYBL2, SDC4, UBE2C</i>	53.33%	13.33%	0.0251
17q23	RPS6KB1, USP32, PAT1, PPM1D, BCAS3, TBX2, MRC2	26.67%	0.00%	0.0498
<b>Losses</b>				
1p36.22	-	6.67%	53.33%	0.0071
22qtel	<i>PARVB, PARVG, PRR5, FNLN1, PPARA, GRAMD4</i>	6.67%	46.67%	0.0176
1p13.1	VANGL1, VTCN1	0.00%	33.33%	0.0211
11q22.3	PDGFD, ALKBH8, RDX <i>CASP-12, -4, -5, -1, CUL5, ATM</i>	0.00%	26.67%	0.0498
Xq25	XIAP, SMARCA1, APLN <i>AIFM1</i>	0.00%	26.67%	0.0498

Table 5. Significant difference between early- and late-onset breast cancers by array-CGH (aberrant genes correlated with early- or late-onset breast cancers were evaluated by using the Fisher's exact test).

### 3. Conclusion

In this report we show that early-onset breast cancer has different genetic alterations as compared with that of late-onset cancer, suggesting that different molecular pathways are involved in the generation of these two types of cancer. The genes strongly associated with early-onset breast cancer such as those in 17q23 amplicon may be useful for deducing the molecular mechanism of breast cancer in young women as well as for serving as candidate biomarkers.

Early-onset breast cancer has been a major health concern and had poor prognosis compared with late-onset in Taiwan. We are interested in comparing the genome aberrations between early- and late-onset breast cancers. Although we study the genome aberrations in Taiwan, we also explore the public data which are associated with early-onset and late-onset breast cancers. The findings can help us to address early-onset breast cancer specific gene aberrations and explore the unique tumor biology in Taiwan through this broad view.

### 4. Acknowledgements

This work is supported by the program for Promoting Academic Excellence of Universities (Phase II, NSC 94-2752-B-010-001-PAE), by a grant from Ministry of Education. Aim for the Top University Plan and by the National Program and a grant from the National Research Program of Genomic Medicine (NSC94-3112-B-010-003 and NSC95-3112-B-010-012) from the National Science Council of Taiwan.

### 5. References


- Adami, H.O., Lipworth, L., Titus-Ernstoff, L., Hsieh, C.C., Hanberg, A., Ahlborg, U., Baron, J., and Trichopoulos, D. (1995). Organochlorine compounds and estrogen-related cancers in women. *Cancer Causes Control* 6: 551-566.
- Adami, H.O., Signorello, L.B., and Trichopoulos, D. (1998). Towards an understanding of breast cancer etiology. *Semin Cancer Biol* 8: 255-262.
- Ahmad, N., and Kumar, R. (2011). Steroid hormone receptors in cancer development: a target for cancer therapeutics. *Cancer Lett* 300: 1-9.
- Anders, C.K., Fan, C., Parker, J.S., Carey, L.A., Blackwell, K.L., Klauber-DeMore, N., and Perou, C.M. (2011). Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? *J Clin Oncol* 29: e18-20.
- Anders, C.K., Hsu, D.S., Broadwater, G., Acharya, C.R., Foekens, J.A., Zhang, Y., Wang, Y., Marcom, P.K., Marks, J.R., Febbo, P.G., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. *J Clin Oncol* 26: 3324-3330.
- Anderson, W.F., Chatterjee, N., Ershler, W.B., and Brawley, O.W. (2002). Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. *Breast Cancer Res Treat* 76: 27-36.
- Anderson, W.F., Chu, K.C., Chatterjee, N., Brawley, O., and Brinton, L.A. (2001). Tumor variants by hormone receptor expression in white patients with node-negative

- breast cancer from the surveillance, epidemiology, and end results database. *J Clin Oncol* 19, 18-27.
- Bai, L., and Rohrschneider, L.R. (2010). s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. *Genes Dev* 24: 1882-1892.
- Baudis, M., and Cleary, M.L. (2001). Progenetix.net: an online repository for molecular cytogenetic aberration data. *Bioinformatics* 17: 1228-1229.
- Benz, C.C. (2008). Impact of aging on the biology of breast cancer. *Crit Rev Oncol Hematol* 66: 65-74.
- Boldt, V., Stacher, E., Halbwedl, I., Popper, H., Hultschig, C., Moinfar, F., Ullmann, R., and Tavassoli, F.A. (2010). Positioning of necrotic lobular intraepithelial neoplasias (LIN, grade 3) within the sequence of breast carcinoma progression. *Genes Chromosomes Cancer* 49: 463-470.
- Bonnier, P., Romain, S., Charpin, C., Lejeune, C., Tubiana, N., Martin, P.M., and Piana, L. (1995). Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. *Int J Cancer* 62: 138-144.
- Briskin, C., and O'Malley, B. (2010). Hormone action in the mammary gland. *Cold Spring Harb Perspect Biol* 2: a003178.
- Butt, S., Borgquist, S., Anagnostaki, L., Landberg, G., and Manjer, J. (2009). Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. *Int J Cancer* 125: 1926-1934.
- Cerliani, J.P., Guillardoy, T., Giulianelli, S., Vaque, J.P., Gutkind, J.S., Vanzulli, S.I., Martins, R., Zeitlin, E., Lamb, C.A., and Lanari, C. (2011). Interaction between FGFR-2, STAT5 and progesterone receptors in breast cancer. *Cancer Res*.
- Chang, K.J., Kuo, W.H., and Wang, M.Y. (2008). The epidemiology of breast cancer in Taiwan. *J. Chinese Oncol. Soc.* 24: 85-93.
- Chen, F., and Capecchi, M.R. (1999). Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy. *Proc Natl Acad Sci U S A* 96: 541-546.
- Cheng, S.H., Tsou, M.H., Liu, M.C., Jian, J.J., Cheng, J.C., Leu, S.Y., Hsieh, C.Y., and Huang, A.T. (2000). Unique features of breast cancer in Taiwan. *Breast Cancer Res Treat* 63: 213-223.
- Chodosh, L.A., D'Cruz, C.M., Gardner, H.P., Ha, S.I., Marquis, S.T., Rajan, J.V., Stairs, D.B., Wang, J.Y., and Wang, M. (1999). Mammary gland development, reproductive history, and breast cancer risk. *Cancer Res* 59: 1765-1771s; discussion 1771s-1772s.
- Colleoni, M., Rotmensz, N., Robertson, C., Orlando, L., Viale, G., Renne, G., Luini, A., Veronesi, P., Intra, M., Orecchia, R., et al. (2002). Very young women (<35 years) with operable breast cancer: features of disease at presentation. *Ann Oncol* 13: 273-279.
- Flucke, U., Flucke, M.T., Hoy, L., Breuer, E., Goebbels, R., Rhiem, K., Schmutzler, R., Winzenried, H., Braun, M., Steiner, S., et al. (2010). Distinguishing medullary carcinoma of the breast from high-grade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach. *Histopathology* 56: 852-859.

- Fridlyand, J., Snijders, A.M., Ylstra, B., Li, H., Olshen, A., Seagraves, R., Dairkee, S., Tokuyasu, T., Ljung, B.M., Jain, A.N., *et al.* (2006). Breast tumor copy number aberration phenotypes and genomic instability. *BMC Cancer* 6: 96.
- Hardy, K.M., Booth, B.W., Hendrix, M.J., Salomon, D.S., and Strizzi, L. (2010). ErbB/EGF signaling and EMT in mammary development and breast cancer. *J Mammary Gland Biol Neoplasia* 15: 191-199.
- Hilakivi-Clarke, L., and Clarke, R. (1998). Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity. *Mol Cell Biochem* 188: 5-12.
- Howell, A., and Evans, G.D. (2011). Hormone replacement therapy and breast cancer. *Recent Results Cancer Res* 188: 115-124.
- Jevtic, M., Velicki, R., Popovic, M., Cemerlic-Adjic, N., Babovic, S.S., and Velicki, L. (2010). Dietary influence on breast cancer. *J BUON* 15: 455-461.
- Kruger, W.M., and Appfelstaedt, J.P. (2007) Young breast cancer patients in the developing world: incidence, choice of surgical treatment and genetic factors. *SA Fam. Pract.* 49: 18-24.
- Lee, K.D., Chen, S.C., Chan, C.H., Lu, C.H., Chen, C.C., Lin, J.T., Chen, M.F., Huang, S.H., Yeh, C.M., and Chen, M.C. (2008). Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. *Cancer Epidemiol Biomarkers Prev* 17: 2647-2655.
- Li, S., Han, B., Liu, G., Ouellet, J., Labrie, F., and Pelletier, G. (2010). Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. *J Histochem Cytochem* 58: 509-515.
- Lin, C.H., Liau, J.Y., Lu, Y.S., Huang, C.S., Lee, W.C., Kuo, K.T., Shen, Y.C., Kuo, S.H., Lan, C., Liu, J.M., *et al.* (2009). Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. *Cancer Epidemiol Biomarkers Prev* 18: 1807-1814.
- McTiernan, A., Irwin, M., and Vongruenigen, V. (2010). Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. *J Clin Oncol* 28: 4074-4080.
- Mellemkjaer, L., Friis, S., Olsen, J.H., Scelo, G., Hemminki, K., Tracey, E., Andersen, A., Brewster, D.H., Pukkala, E., McBride, M.L., *et al.* (2006). Risk of second cancer among women with breast cancer. *Int J Cancer* 118: 2285-2292.
- Mita, K., Zhang, Z., Ando, Y., Toyama, T., Hamaguchi, M., Kobayashi, S., Hayashi, S., Fujii, Y., Iwase, H., and Yamashita, H. (2007). Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. *Jpn J Clin Oncol* 37: 575-582.
- Muti, P. (2005). The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiologic evidence. *Recent Results Cancer Res* 166: 245-256.
- Okoh, V., Deoraj, A., and Roy, D. (2011). Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. *Biochim Biophys Acta* 1815: 115-133.
- Pampalakis, G., Prosnikli, E., Agalioi, T., Vlahou, A., Zoumpourlis, V., and Sotiropoulou, G. (2009). A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. *Cancer Res* 69: 3779-3787.

- Phipps, A.I., Chlebowski, R.T., Prentice, R., McTiernan, A., Wactawski-Wende, J., Kuller, L.H., Adams-Campbell, L.L., Lane, D., Stefanick, M.L., Vitolins, M., *et al.* (2011). Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. *J Natl Cancer Inst* 103: 470-477.
- Reis-Filho, J.S., Simpson, P.T., Jones, C., Steele, D., Mackay, A., Irvani, M., Fenwick, K., Valgeirsson, H., Lambros, M., Ashworth, A., *et al.* (2005). Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. *J Pathol* 207: 1-13.
- Roussos, E.T., Wang, Y., Wyckoff, J.B., Sellers, R.S., Wang, W., Li, J., Pollard, J.W., Gertler, F.B., and Condeelis, J.S. (2010). Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. *Breast Cancer Res* 12: R101.
- Russo, J., and Russo, I.H. (1994). Toward a physiological approach to breast cancer prevention. *Cancer Epidemiol Biomarkers Prev* 3: 353-364.
- Sanderson, M., Williams, M.A., Daling, J.R., Holt, V.L., Malone, K.E., Self, S.G., and Moore, D.E. (1998). Maternal factors and breast cancer risk among young women. *Paediatr Perinat Epidemiol* 12: 397-407.
- Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., *et al.* (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* 100: 8418-8423.
- Sotiriou, C., Neo, S.Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., Martiat, P., Fox, S.B., Harris, A.L., and Liu, E.T. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc Natl Acad Sci U S A* 100: 10393-10398.
- Tamimi, R.M., Colditz, G.A., Wang, Y., Collins, L.C., Hu, R., Rosner, B., Irie, H.Y., Connolly, J.L., and Schnitt, S.J. (2011). Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. *Breast Cancer Res Treat.*
- Torres-Arzayus, M.I., Zhao, J., Bronson, R., and Brown, M. (2010). Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. *Cancer Res* 70: 4102-4111.
- Trepp, R., Padberg, B.C., Varga, Z., Cathomas, R., Inauen, R., and Reinhart, W.H. (2010). Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. *Pathol Res Pract* 206: 334-337.
- Trichopoulos, D., Adami, H.O., Ekblom, A., Hsieh, C.C., and Ligiou, P. (2008). Early life events and conditions and breast cancer risk: from epidemiology to etiology. *Int J Cancer* 122: 481-485.
- Wu, A.H., McKean-Cowdin, R., and Tseng, C.C. (2011). Birth weight and other prenatal factors and risk of breast cancer in Asian-Americans. *Breast Cancer Res Treat.*
- Xu, Y., Bismar, T.A., Su, J., Xu, B., Kristiansen, G., Varga, Z., Teng, L., Ingber, D.E., Mammoto, A., Kumar, R., *et al.* (2010). Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. *J Exp Med* 207: 2421-2437.
- Yaghjian, L., and Colditz, G.A. (2011). Estrogens in the breast tissue: a systematic review. *Cancer Causes Control* 22: 529-540.

- Yankaskas, B.C. (2005). Epidemiology of breast cancer in young women. *Breast Dis* 23: 3-8.
- Yu, G.P., Schantz, S.P., Neugut, A.I., and Zhang, Z.F. (2006). Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). *Cancer Causes Control* 17: 411-420.



## **Breast Cancer - Recent Advances in Biology, Imaging and Therapeutics**

Edited by Dr. Susan Done

ISBN 978-953-307-730-7

Hard cover, 428 pages

**Publisher** InTech

**Published online** 14, December, 2011

**Published in print edition** December, 2011

In recent years it has become clear that breast cancer is not a single disease but rather that the term encompasses a number of molecularly distinct tumors arising from the epithelial cells of the breast. There is an urgent need to better understand these distinct subtypes and develop tailored diagnostic approaches and treatments appropriate to each. This book considers breast cancer from many novel and exciting perspectives. New insights into the basic biology of breast cancer are discussed together with high throughput approaches to molecular profiling. Innovative strategies for diagnosis and imaging are presented as well as emerging perspectives on breast cancer treatment. Each of the topics in this volume is addressed by respected experts in their fields and it is hoped that readers will be stimulated and challenged by the contents.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Ming-Ta Hsu, Ching Cheng, Chian-Feng, Chen, Yiin-Jeng Jong, Chien-Yi Tung, Yann-Jang Chen, Sheng Wang-Wuu, Ling-Hui Li, Shih-Feng Tsai, Mei-Hua Tsou, Skye H. Cheng, Chii-Ming Chen, Andrew T. Huang, Chi-Hung Lin and Ming-Ta Hsu (2011). Comparison of Genome Aberrations Between Early-Onset and Late-Onset Breast Cancer, *Breast Cancer - Recent Advances in Biology, Imaging and Therapeutics*, Dr. Susan Done (Ed.), ISBN: 978-953-307-730-7, InTech, Available from: <http://www.intechopen.com/books/breast-cancer-recent-advances-in-biology-imaging-and-therapeutics/comparison-of-genome-aberrations-between-early-onset-and-late-onset-breast-cancer>

# **INTECH**

open science | open minds

### **InTech Europe**

University Campus STeP Ri

Slavka Krautzeka 83/A

51000 Rijeka, Croatia

Phone: +385 (51) 770 447

Fax: +385 (51) 686 166

[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai

No.65, Yan An Road (West), Shanghai, 200040, China

中国上海市延安西路65号上海国际贵都大饭店办公楼405单元

Phone: +86-21-62489820

Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.